Analysts Set Urogen Pharma (NASDAQ:URGN) PT at $34.13

Shares of Urogen Pharma (NASDAQ:URGN) have received an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $34.1250.

A number of research firms recently issued reports on URGN. Jefferies Financial Group began coverage on Urogen Pharma in a report on Friday, April 10th. They set a “buy” rating and a $40.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday. Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a research note on Monday, March 2nd. Finally, D. Boral Capital reissued a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a research report on Tuesday, March 31st.

Insider Activity at Urogen Pharma

In other news, General Counsel Jason Drew Smith sold 7,479 shares of Urogen Pharma stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $147,261.51. Following the transaction, the general counsel directly owned 51,326 shares of the company’s stock, valued at $1,010,608.94. This trade represents a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mark Schoenberg sold 7,373 shares of Urogen Pharma stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $145,174.37. Following the completion of the transaction, the insider directly owned 144,985 shares in the company, valued at approximately $2,854,754.65. This trade represents a 4.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 4.70% of the company’s stock.

Hedge Funds Weigh In On Urogen Pharma

Several institutional investors and hedge funds have recently bought and sold shares of the business. Osaic Holdings Inc. grew its stake in Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after acquiring an additional 3,070 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares in the last quarter. State of Wyoming purchased a new position in Urogen Pharma during the 3rd quarter valued at about $66,000. Russell Investments Group Ltd. grew its stake in Urogen Pharma by 1,594.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after acquiring an additional 3,125 shares in the last quarter. Finally, Strs Ohio purchased a new position in Urogen Pharma during the 3rd quarter valued at about $76,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Urogen Pharma Stock Up 4.1%

NASDAQ:URGN opened at $26.06 on Monday. The business’s 50-day moving average price is $19.95 and its 200 day moving average price is $21.06. The firm has a market cap of $1.27 billion, a P/E ratio of -8.14 and a beta of 1.43. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $30.00.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.12. The firm had revenue of $37.84 million for the quarter, compared to analyst estimates of $39.92 million. Sell-side analysts expect that Urogen Pharma will post -1.2 EPS for the current year.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.